GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
ES2259800T3
(es)
|
1990-06-11 |
2006-10-16 |
Gilead Sciences, Inc. |
Procedimientos de uso de ligandos de acido nucleico.
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
EP0752248B1
(en)
|
1992-11-13 |
2000-09-27 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
AU6703198A
(en)
|
1997-03-21 |
1998-10-20 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
ES2340745T3
(es)
|
1998-12-23 |
2010-06-08 |
Pfizer Inc. |
Anticuerpos monoclonales humanos contra ctla-4.
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
US6936704B1
(en)
|
1999-08-23 |
2005-08-30 |
Dana-Farber Cancer Institute, Inc. |
Nucleic acids encoding costimulatory molecule B7-4
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
AU783063B2
(en)
|
1999-10-28 |
2005-09-22 |
Seyedhossein Aharinejad |
Use of CSF-1 inhibitors
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート,エルエルシー |
Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用
|
ATE378403T1
(de)
|
2000-11-30 |
2007-11-15 |
Medarex Inc |
Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
|
GB0100621D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VI
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
LT1507556T
(lt)
|
2002-05-02 |
2016-10-10 |
Wyeth Holdings Llc |
Kalicheamicino darinio ir nešiklio konjugatai
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
EP2330130B1
(en)
|
2002-10-17 |
2014-08-27 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
AU2003285878B2
(en)
|
2002-11-07 |
2011-04-28 |
Immunogen, Inc. |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
|
EP1572744B1
(en)
|
2002-12-16 |
2010-06-09 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
KR20060079180A
(ko)
|
2003-07-02 |
2006-07-05 |
노보 노르디스크 에이/에스 |
Nk 세포 활성을 조절하기 위한 조성물 및 방법
|
ES2619171T3
(es)
|
2003-07-24 |
2017-06-23 |
Innate Pharma S.A. |
Métodos y composiciones para aumentar la eficacia de anticuerpos terapéuticos utilizando compuestos para la potenciación de linfocitos NK
|
EP1791868B1
(en)
|
2004-07-01 |
2011-02-23 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
EP1836225B1
(en)
|
2005-01-06 |
2011-11-02 |
Novo Nordisk A/S |
Kir-binding agents and methods of use thereof
|
JP5855326B2
(ja)
|
2005-01-06 |
2016-02-09 |
ノヴォ ノルディスク アー/エス |
抗kir組み合わせ治療および方法
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
AU2006301163B2
(en)
|
2005-10-14 |
2012-02-23 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
GB0521991D0
(en)
|
2005-10-28 |
2005-12-07 |
Univ Dundee |
Siglec-9 binding agents
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
EP3222634A1
(en)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
US8747847B2
(en)
|
2008-02-11 |
2014-06-10 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
CA2728734A1
(en)
|
2008-06-25 |
2009-12-30 |
Braasch Biotech Llc |
Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof
|
DE102008036127A1
(de)
|
2008-08-01 |
2010-02-04 |
Emitec Gesellschaft Für Emissionstechnologie Mbh |
Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Pd-1 길항제 및 그의 사용 방법
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
US20120064096A1
(en)
|
2009-03-17 |
2012-03-15 |
Universite De La Mediterranee |
BTLA Antibodies and Uses Thereof
|
EA201270228A1
(ru)
|
2009-07-31 |
2012-09-28 |
Медарекс, Инк. |
Полноценные человеческие антитела к btla
|
CN102666581A
(zh)
|
2009-08-31 |
2012-09-12 |
艾普利穆恩公司 |
用于抑制移植物排斥的方法和组合物
|
KR101573109B1
(ko)
|
2009-11-24 |
2015-12-01 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
RU2617966C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
WO2011140249A2
(en)
|
2010-05-04 |
2011-11-10 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
EA035033B1
(ru)
|
2010-11-22 |
2020-04-20 |
Иннейт Фарма Са |
Способ лечения гематологического предракового или гематологического ракового заболеваний
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
LT2785375T
(lt)
|
2011-11-28 |
2020-11-10 |
Merck Patent Gmbh |
Anti-pd-l1 antikūnai ir jų panaudojimas
|
CN104159921B
(zh)
|
2011-12-15 |
2018-05-04 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
KR20140107413A
(ko)
|
2011-12-16 |
2014-09-04 |
화이자 인코포레이티드 |
암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합
|
RU2014136332A
(ru)
|
2012-02-06 |
2016-03-27 |
Дженентек, Инк. |
Композиции и способы применения ингибиторов csf1r
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
MY186099A
(en)
|
2012-05-31 |
2021-06-22 |
Genentech Inc |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
CN115093480A
(zh)
|
2012-05-31 |
2022-09-23 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
RU2718751C2
(ru)
|
2012-08-31 |
2020-04-14 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
|
RS56624B1
(sr)
|
2012-10-02 |
2018-03-30 |
Bristol Myers Squibb Co |
Kombinacija anti-kir antitela i anti-pd-1 antitela u lečenju kancera
|
US9789182B2
(en)
|
2012-10-23 |
2017-10-17 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
|
WO2014094122A1
(en)
|
2012-12-17 |
2014-06-26 |
Trillium Therapeutics Inc. |
Treatment of cd47+ disease cells with sirp alpha-fc fusions
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
WO2014127785A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
CA2901368A1
(en)
|
2013-02-28 |
2014-09-04 |
University Court Of The University Of Edinburgh |
Csf1 therapeutics
|
WO2014165082A2
(en)
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
US20160067337A1
(en)
|
2013-03-14 |
2016-03-10 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
AU2014230741B2
(en)
|
2013-03-15 |
2017-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
US10450361B2
(en)
|
2013-03-15 |
2019-10-22 |
Momenta Pharmaceuticals, Inc. |
Methods related to CTLA4-Fc fusion proteins
|
EP2992017B1
(en)
|
2013-05-02 |
2020-11-18 |
AnaptysBio, Inc. |
Antibodies directed against programmed death-1 (pd-1)
|
US10005839B2
(en)
|
2013-05-17 |
2018-06-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antagonist of the BTLA/HVEM interaction for use in therapy
|
JP6563906B2
(ja)
|
2013-05-31 |
2019-08-21 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Pd−1に結合する抗原結合蛋白質
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
WO2014207748A1
(en)
|
2013-06-27 |
2014-12-31 |
Alexander Biro |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
PL3021869T3
(pl)
|
2013-07-16 |
2020-11-16 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT
|
KR20220025174A
(ko)
|
2013-08-01 |
2022-03-03 |
위니베르시트카솔리끄드루뱅 |
항garp 단백질 항체와 그 용도
|
AU2013400609B9
(en)
|
2013-09-13 |
2020-03-05 |
Beigene Switzerland Gmbh |
Anti-PD1 antibodies and their use as therapeutics and diagnostics
|
RS64268B1
(sr)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
AU2014339900B2
(en)
|
2013-10-25 |
2019-10-24 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
US20160263087A1
(en)
|
2013-11-08 |
2016-09-15 |
Iteos Therapeutics |
Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
US9126984B2
(en)
|
2013-11-08 |
2015-09-08 |
Iteos Therapeutics |
4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
|
CN105744955B
(zh)
|
2013-11-25 |
2020-03-20 |
希凯姆生物治疗有限公司 |
用于癌症治疗的包含抗ceacam1抗体和抗pd抗体的组合物
|
EP3082802B1
(en)
|
2013-12-03 |
2020-02-26 |
Iomet Pharma Ltd. |
Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
JP2017509319A
(ja)
|
2014-01-15 |
2017-04-06 |
カドモン コーポレイション,リミティド ライアビリティ カンパニー |
免疫調節剤
|
US10711272B2
(en)
|
2014-01-21 |
2020-07-14 |
City Of Hope |
CTLA-4 aptamer siRNA species
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EA201691361A1
(ru)
|
2014-01-28 |
2016-12-30 |
Бристол-Маерс Сквибб Компани |
Антитела к lag-3 для лечения гематологических злокачественных опухолей
|
WO2015121812A1
(en)
|
2014-02-12 |
2015-08-20 |
Iteos Therapeutics |
Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
|
EP3119763A1
(en)
|
2014-03-18 |
2017-01-25 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
CA2944240A1
(en)
|
2014-04-04 |
2015-10-08 |
Iomet Pharma Ltd |
Indole derivatives as ido/tdo inhibitors
|
BR112016026197A2
(pt)
|
2014-05-13 |
2018-02-20 |
Medimmune Limited |
anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de câncer de pulmão de não pequenas células
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
US9603836B2
(en)
|
2014-05-15 |
2017-03-28 |
Iteos Therapeutics |
Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
US9885721B2
(en)
|
2014-05-29 |
2018-02-06 |
Spring Bioscience Corporation |
PD-L1 antibodies and uses thereof
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
WO2016000619A1
(en)
|
2014-07-03 |
2016-01-07 |
Beigene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
US20160009805A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
RU2722212C9
(ru)
|
2014-08-05 |
2020-07-23 |
СиБи ТЕРЕПЬЮТИКС, ИНК. |
Анти-pd-l1 антитела
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016032334A1
(en)
|
2014-08-28 |
2016-03-03 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
|
JP2017532025A
(ja)
|
2014-09-10 |
2017-11-02 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
交差反応性siglec抗体
|
US10676523B2
(en)
|
2014-09-16 |
2020-06-09 |
Innate Pharma |
Treatment regimens using anti-NKG2A antibodies
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
WO2016071293A2
(en)
|
2014-11-03 |
2016-05-12 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
US9938356B2
(en)
|
2014-11-10 |
2018-04-10 |
Medimmune Limited |
Binding molecules specific for CD73 and uses thereof
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
EP3253796A1
(en)
|
2015-02-03 |
2017-12-13 |
Université Catholique de Louvain |
Anti-garp protein and uses thereof
|
EP3295951B1
(en)
|
2015-02-19 |
2020-04-22 |
Compugen Ltd. |
Anti-pvrig antibodies and methods of use
|
EP3978929A1
(en)
|
2015-02-19 |
2022-04-06 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
CA2978942A1
(en)
|
2015-03-13 |
2016-09-22 |
Cytomx Therapeutics, Inc. |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
MX2017011951A
(es)
|
2015-03-17 |
2018-06-15 |
Pfizer |
Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
|
US10836827B2
(en)
|
2015-03-30 |
2020-11-17 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
WO2016181349A1
(en)
|
2015-05-14 |
2016-11-17 |
Pfizer Inc. |
Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Tigit結合劑和彼之用途
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
US9902772B2
(en)
|
2015-07-22 |
2018-02-27 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind LAG3
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
PT3328419T
(pt)
|
2015-07-30 |
2021-11-26 |
Macrogenics Inc |
Moléculas de ligação pd-1 e métodos de utilização
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
EP3331901A1
(en)
|
2015-08-07 |
2018-06-13 |
Pieris Pharmaceuticals GmbH |
Novel fusion polypeptide specific for lag-3 and pd-1
|
EP3334733A1
(en)
|
2015-08-10 |
2018-06-20 |
Pfizer Inc |
3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
MA48579A
(fr)
|
2015-09-01 |
2020-03-18 |
Agenus Inc |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
FI3354729T3
(fi)
|
2015-09-24 |
2024-04-23 |
Daiichi Sankyo Co Ltd |
Anti-garp-vasta-aine
|
AU2016331052B2
(en)
|
2015-10-01 |
2023-08-03 |
Potenza Therapeutics, Inc. |
Anti-TIGIT antigen-binding proteins and methods of use thereof
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
EP3368575A2
(en)
|
2015-10-29 |
2018-09-05 |
Alector LLC |
Anti-siglec-9 antibodies and methods of use thereof
|
KR102317574B1
(ko)
|
2015-11-18 |
2021-10-26 |
머크 샤프 앤드 돔 코포레이션 |
Pd1 및/또는 lag3 결합제
|
WO2017087901A2
(en)
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
KR20180086502A
(ko)
|
2015-12-16 |
2018-07-31 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항원-결합 단편
|
EP3402516A4
(en)
|
2016-01-12 |
2020-01-08 |
Palleon Pharmaceuticals Inc. |
USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
|
US9624185B1
(en)
|
2016-01-20 |
2017-04-18 |
Yong Xu |
Method for preparing IDO inhibitor epacadostat
|
CN111491362B
(zh)
|
2016-02-02 |
2023-10-24 |
华为技术有限公司 |
确定发射功率的方法、用户设备和基站
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
WO2017173091A1
(en)
|
2016-03-30 |
2017-10-05 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
|
DK3458478T3
(da)
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
JP6794442B2
(ja)
|
2016-05-30 |
2020-12-02 |
アステラス製薬株式会社 |
新規な遺伝子組換えワクシニアウイルス
|
SG11201811064TA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Delta Ltd |
Binding molecules binding pd-l1 and lag-3
|
CN109311993B
(zh)
|
2016-06-20 |
2022-12-20 |
F-星治疗有限公司 |
Lag-3结合元件
|
TWI757304B
(zh)
|
2016-06-23 |
2022-03-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Lag-3抗體、其抗原結合片段及其醫藥用途
|
WO2018017864A2
(en)
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
US20190185571A1
(en)
|
2016-07-28 |
2019-06-20 |
Musc Foundation For Research Development |
Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
|
EA201990296A1
(ru)
|
2016-08-05 |
2019-08-30 |
Аллакос, Инк. |
Антитела против siglec-7 для лечения рака
|
JP7100018B2
(ja)
|
2016-08-08 |
2022-07-12 |
アセチロン ファーマシューティカルズ インコーポレイテッド |
ヒストンデアセチラーゼ6阻害剤及びcd20阻害抗体の薬学的組み合わせならびにその使用
|
EP3498840A4
(en)
|
2016-08-15 |
2020-05-06 |
National University Corporation Hokkaido University |
ANTI-LAG-3 ANTIBODIES
|
DK3347379T5
(da)
|
2016-08-17 |
2020-06-15 |
Compugen Ltd |
Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
JP7212821B2
(ja)
|
2016-10-13 |
2023-01-26 |
チア・タイ・ティエンチン・ファーマシューティカル・グループ・カンパニー・リミテッド |
抗lag-3抗体および組成物
|
BR112019008861A2
(pt)
|
2016-11-01 |
2019-07-09 |
Anaptysbio Inc |
anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
|
UY37463A
(es)
|
2016-11-02 |
2018-05-31 |
Glaxosmithkline Ip No 2 Ltd |
Proteínas de unión
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
WO2018106529A1
(en)
|
2016-12-08 |
2018-06-14 |
Eli Lilly And Company |
Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
|
CN107058315B
(zh)
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
MX2019006897A
(es)
|
2016-12-13 |
2019-08-22 |
Astellas Pharma Inc |
Anticuerpo anti cd73 humana.
|
US10537637B2
(en)
|
2017-01-05 |
2020-01-21 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
WO2019000146A1
(zh)
|
2017-06-26 |
2019-01-03 |
深圳市博奥康生物科技有限公司 |
一种人程序性死亡受体1基因的siRNA及其应用
|
US11447545B2
(en)
|
2017-07-10 |
2022-09-20 |
Innate Pharma |
Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
|
CN111263769B
(zh)
|
2017-07-10 |
2024-01-02 |
先天制药公司 |
Siglec-9中和性抗体
|
WO2019242505A1
(zh)
*
|
2018-06-17 |
2019-12-26 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
MX2021001353A
(es)
*
|
2018-08-03 |
2021-04-13 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3.
|
CN109762067B
(zh)
*
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|